This scoping review found that chemotherapy-induced alopecia in breast cancer patients, especially when using anthracycline- and taxane-based regimens, occurs at higher rates and with more persistence than historically reported.
February 2026 in “Clinical Cancer Research” This study found that misinformation about breast cancer symptom management is highly prevalent on Instagram, with over half of the content deemed misleading, especially posts promoting unproven remedies, and commercial intent present in many posts, mainly created by influencers rather than healthcare professionals.
December 2025 in “Clinical and Translational Science” This review highlights that chemotherapy-induced skin toxicities from EGFR inhibitors in breast cancer treatment can significantly impact patient quality of life and treatment adherence, emphasizing the importance of proactive management and patient discussions.
November 2025 in “Journal of Cancer Research and Clinical Oncology” This study from China found that although traditional surgical techniques remain common, endoscopic-assisted surgery is linked with higher patient-reported satisfaction, suggesting its valuable potential for broader application in clinical settings. Factors like reduced bra cup size, surgical method, and implant placement influenced patient satisfaction.
November 2025 in “Cancer Reports” In this study, women who underwent chemotherapy for breast cancer in Islamabad, Pakistan, reported significant physical and psychological challenges, as well as economic strain; the authors concluded that government support and improved pre-treatment counseling could help mitigate these issues.
September 2025 in “International Journal of Research in Medical Sciences” This study found that breast cancer treatment with chemotherapy, radiotherapy, and/or hormonal therapy led to a significant increase in blood urea and creatinine levels, indicating nephrotoxicity among non-diabetic, non-cardiac post-menopausal patients with infiltrating ductal carcinoma.
July 2025 in “Jurnal Farmasi Sains dan Praktis” This study found that breast cancer patients treated with the docetaxel-doxorubicin regimen experienced various adverse drug reactions, with nausea being the most common and mainly mild in severity.
December 2024 in “Cureus” This study observed that among breast cancer patients at Jinnah Hospital, Lahore, common chemotherapy side effects impacted dietary patterns, leading many patients to be moderately malnourished, while 82% were overweight or obese, posing a higher risk of cancer recurrence.
November 2024 in “Deleted Journal” This study assessed zinc concentrations in breast milk from 58 Palestinian lactating women and found that breast milk zinc levels varied with demographics such as age, urban living, employment status, and intake of zinc-rich drinks.
July 2024 in “Journal of Investigative Dermatology” 5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
This thesis presents the development of the Breast Utility Instrument (BUI), a new tool for assessing health-related quality of life specifically in breast cancer patients.
March 2021 in “Journal of Evolution of Medical and Dental Sciences” In this study, all patients receiving chemotherapy for breast carcinoma experienced chemotoxicities like hair loss, nausea, and fatigue, with no one regimen identified as more toxic than another.
January 2020 in “Mastology” This study reports a case of a 28-year-old woman diagnosed with metastatic breast cancer through bone marrow analysis using flow cytometry and immunohistochemistry, highlighting the potential of flow cytometry as a valuable diagnostic tool for detecting solid tumors.
September 2014 in “Springer eBooks” This review discusses the evaluation and management of breast pain, or mastalgia, highlighting non-pharmacologic therapies and the limited role of surgical interventions, but reports no new clinical findings.
May 2012 in “Journal of Clinical Oncology” This study found a significant association between male breast cancers and exposure to finasteride and dutasteride, with an estimated additional case per 564 men taking these drugs.
March 2023 in “JAAD case reports” This paper outlines that treatments reducing estrogen for estrogen receptor-positive breast cancer, such as SERMs and AIs, significantly improve life expectancy but may lead to alopecia in 15% to 25% of patients.
279 citations
,
June 1990 in “Journal of Clinical Oncology” The study found that for positive-node breast cancer patients aged 50 and older, adding chemotherapy to tamoxifen significantly improved disease-free survival compared to tamoxifen alone.
118 citations
,
November 2024 in “World Journal of Biology Pharmacy and Health Sciences” This study highlights that the ACIP strongly recommends COVID-19 vaccination and booster doses for pregnant women, those breastfeeding, or trying to conceive, due to the safety of non-live vaccines in these groups and the protection they also offer to infants.
90 citations
,
December 2007 in “Current Oncology” This review discusses management strategies for sexual side effects of aromatase inhibitors in postmenopausal breast cancer patients and reports no original clinical findings.
68 citations
,
May 2012 in “Annals of Oncology” This study reports that permanent and severe alopecia is a newly identified complication of the FEC 100–docetaxel regimen used for adjuvant breast cancer treatment.
67 citations
,
April 2018 in “JAMA Dermatology” This study found that endocrine therapy for breast cancer is associated with a pattern of hair loss similar to androgenetic alopecia, negatively impacting quality of life despite mild severity.
59 citations
,
August 2018 in “The oncologist” This study found that permanent chemotherapy-induced alopecia was relatively common three years after treatment among breast cancer patients receiving adjuvant chemotherapy, particularly those on taxane-based regimens.
32 citations
,
March 2018 in “Neoplasia” This study suggests that nephronectin (NPNT) could serve as a novel prognostic marker for poor prognosis in a subgroup of breast cancer patients, associated with specific NPNT staining patterns.
31 citations
,
March 2017 in “Journal of The American Academy of Dermatology” This study observed various patterns of permanent alopecia in breast cancer patients treated with taxanes and adjuvant hormonal chemotherapy, hypothesizing disruptions in hair follicle cycles due to chemoinflammatory and hormonal factors.
21 citations
,
March 2019 in “Critical Reviews in Clinical Laboratory Sciences” This review discusses the role of the androgen receptor in breast cancer diagnosis and treatment, and notes a lack of new research results on its therapeutic potential.
21 citations
,
April 2016 in “International Journal of Oncology” This study found that treatment with the GnRH agonist Triptorelin significantly decreased invasion and expression of S100A4 and CYR61 in certain breast cancer cells, suggesting a potential role in slowing cancer progression.
15 citations
,
July 2023 in “EClinicalMedicine” This review discusses the toxicities associated with antibody-drug conjugates in breast cancer treatment and proposes strategies for monitoring and managing these adverse effects, but it reports no new clinical results.
15 citations
,
June 2014 in “Integrative cancer therapies” This study found that an 8-week practice of pranic meditation was associated with improved quality of life and mental health scores in breast cancer survivors, though further research is needed for confirmation.
12 citations
,
February 2023 in “Supportive Care in Cancer”
11 citations
,
October 2015 in “Journal der Deutschen Dermatologischen Gesellschaft” This study observed that women post-bariatric surgery may be at increased risk for dermatological signs of malnutrition during subsequent pregnancies, highlighting the need for dermatologists to recognize these early symptoms.